DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global Immunology Partnering 2010-2017: Deal trends, players and financials" report to their offering.

Global Immunology Partnering 2010 to 2017 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

Global Immunology Partnering 2010 to 2017 includes:

In Global Immunology Partnering 2010 to 2017, available deals and contracts are listed by:

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

Chapter 3 -Financial deal terms for Immunology partnering

Chapter 4 - Leading Immunology deals and dealmakers

Chapter 5 - Immunology contract document directory

Chapter 6 - Immunology dealmaking by therapeutic target

For more information about this report visit http://www.researchandmarkets.com/research/snnbxb/global_immunology

View source version on businesswire.com: http://www.businesswire.com/news/home/20170503006019/en/

Here is the original post:
Global Immunology Partnering Deal Trends, Players and Financials Analysis Report 2010-2017 - Research and Markets - Yahoo Finance